Tag: Algernon Pharmaceuticals Inc.

Debra BorchardtJune 5, 2023
lab-bottle-mix-unsplash.jpg

4min00
Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF)announced that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of an intravenous (IV) formulation of AP-188 (DMT). AGN Neuro is the world’s first company to investigate DMT for both the treatment […]

StaffJanuary 11, 2023
daily-hit.jpg

4min00
The Daily Hit is a recap of cannabis business news for Jan. 11, 2023. ON THE SITE Connecticut Recreational Cannabis Sales Top $250,000 on Day One According to Biotrack, the cannabis technology platform Connecticut uses to trace marijuana inventory from seed to sale, those seven retailers passed the $250,000 mark by 5 p.m. after just […]

Adam JacksonOctober 24, 2022
dmt-1280x720.webp

4min01
Canadian clinical stage drug development company, Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF), has entered a clinical trial agreement with Yale University to study DMT for the treatment of depression. Algernon will provide DMT for the study in return for intellectual property rights with Yale around the clinical use of the drug. The company will […]

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.